Image of fictitious patient and healthcare professional

ZEJULA (niraparib) - the only once daily oral PARPi monotherapy regardless of biomarker status in platinum responsive advanced ovarian cancer patients.1

ZEJULA (niraparib) is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

FIGO, Federation of Gynaecology and Obstetrics; PARPi, Poly-ADP ribose polymerase inhibitors.

Reference

  1. Zejula (niraparib) Summary of product characteristics (Last Accessed: April 2024).

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2024 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

April 2024 | PM-GB-NRP-WCNT-220017 (V2.0)